Get the Stockscreener App
24.92
2.64%
0.64
Royalty Pharma Plc stock is traded at $24.92, with a volume of 6.52M.
It is up +2.64% in the last 24 hours and down -4.96% over the past month.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$24.28
Open:
$24.34
24h Volume:
6.52M
Relative Volume:
2.52
Market Cap:
$11.07B
Revenue:
$2.27B
Net Income/Loss:
$1.15B
P/E Ratio:
221.51
EPS:
0.1125
Net Cash Flow:
$2.80B
1W Performance:
+0.32%
1M Performance:
-4.96%
6M Performance:
-6.42%
1Y Performance:
-7.94%
1-Day Range:
$24.32
$25.00
1-Week Range:
$24.05
$25.28
52-Week Range:
$24.05
$31.66
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma Plc
Sector
Industry
Phone
(212) 883-0200
Address
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
24.92 | 11.07B | 2.27B | 1.15B | 2.80B | 2.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-03-24 | Downgrade | UBS | Buy → Neutral |
| Jun-14-22 | Resumed | UBS | Buy |
| May-13-22 | Initiated | Scotiabank | Sector Outperform |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-14-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Oct-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-30-21 | Initiated | Tigress Financial | Buy |
| Nov-09-20 | Upgrade | UBS | Neutral → Buy |
| Jul-14-20 | Initiated | Evercore ISI | In-line |
| Jul-13-20 | Initiated | BofA Securities | Buy |
| Jul-13-20 | Initiated | Citigroup | Neutral |
| Jul-13-20 | Initiated | Cowen | Outperform |
| Jul-13-20 | Initiated | Goldman | Neutral |
| Jul-13-20 | Initiated | JP Morgan | Neutral |
| Jul-13-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-13-20 | Initiated | SunTrust | Buy |
| Jul-13-20 | Initiated | UBS | Neutral |
View All
Royalty Pharma Plc Stock (RPRX) Latest News
Wellington Management Group LLP Sells 39,598 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Franklin Resources Inc. Grows Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Barclays PLC Raises Stake in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Reaches New 12-Month LowWhat's Next? - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Stake Boosted by Geode Capital Management LLC - MarketBeat
Synovus Financial Corp Sells 118,379 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Relative Strength Alert For Royalty Pharma - Nasdaq
3 High-Yield Dividend Stocks to Buy in 2025 and Hold for a Decade or Longer - The Motley Fool
Royalty Pharma stock hits 52-week low at $25.1 amid market shifts - Investing.com Australia
Royalty Pharma stock hits 52-week low at $25.1 amid market shifts By Investing.com - Investing.com South Africa
State Street Corp Grows Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Executive Wealth Management LLC Sells 22,839 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Kovitz Investment Group Partners LLC Sells 50,665 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Point72 Asset Management L.P. Takes $14.90 Million Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
The Manufacturers Life Insurance Company Has $4.30 Million Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Two Sigma Advisers LP Increases Stock Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
(RPRX) Investment Analysis - Stock Traders Daily
Point72 DIFC Ltd Purchases New Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Is Royalty Pharma (RPRX) the Best All-Time Low Stock to Buy Right Now? - Insider Monkey
2 Exceptional Dividend Stocks Near 52-Week Lows You Could Regret Not Buying on the Dips - The Motley Fool
ArrowMark Colorado Holdings LLC Invests $2.03 Million in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
PDT Partners LLC Sells 20,502 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Position Decreased by Glenmede Trust Co. NA - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Purchased by Bank of Montreal Can - MarketBeat
45,965 Shares in Royalty Pharma plc (NASDAQ:RPRX) Purchased by D.A. Davidson & CO. - MarketBeat
Eventide Asset Management LLC Buys 22,993 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
How Royalty Pharma, Open Text And VICI Properties Can Put Cash In Your Pocket - Yahoo Finance
Charles Schwab Investment Management Inc. Has $84.92 Million Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Citigroup Inc. Has $14.95 Million Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma to Present at Upcoming Investor Conferences - The Manila Times
Royalty Pharma to Present at Two Major Healthcare Investor Conferences in December | RPRX Stock News - StockTitan
Why Royalty Pharma (RPRX) is the Cheapest Stock to Buy on Robinhood? - MSN
Dai ichi Life Insurance Company Ltd Boosts Stock Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Qsemble Capital Management LP Takes Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
10 Cheapest Stocks to Buy On Robinhood - Insider Monkey
(RPRX) Trading Advice - Stock Traders Daily
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Raises Stake in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Thrivent Financial for Lutherans Purchases 168,905 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Overbrook Management Corp Sells 59,504 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Acquired by Victory Capital Management Inc. - MarketBeat
RPRXRoyalty Pharma plc Latest Stock News & Market Updates - StockTitan
Amalgamated Bank Sells 48,057 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Undercovered Dozen: Aurora Cannabis, FREYR Battery, Royalty Pharma, Talos Energy + - Seeking Alpha
Royalty Pharma stock hits 52-week low at $25.2 amid market shifts - Investing.com India
Royalty Pharma (NASDAQ:RPRX) Sets New 52-Week LowTime to Sell? - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Bought by Simplify Asset Management Inc. - MarketBeat
Royalty Pharma Plc Stock (RPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Royalty Pharma Plc Stock (RPRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| RIGGS RORY B | Director |
Jan 03 '24 |
Sale |
27.79 |
199,098 |
5,532,276 |
55,801 |
| RIGGS RORY B | Director |
Jan 04 '24 |
Sale |
27.55 |
35,702 |
983,504 |
20,099 |
| Avara Management Ltd | 10% Owner |
Dec 29 '23 |
Sale |
28.04 |
65,803 |
1,845,406 |
2,477,520 |
| Avara Management Ltd | 10% Owner |
Dec 28 '23 |
Sale |
28.20 |
209,863 |
5,918,934 |
2,543,323 |
| Avara Management Ltd | 10% Owner |
Dec 27 '23 |
Sale |
28.01 |
41,729 |
1,168,754 |
2,753,186 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):